Premium
Fetal cardiac biometry and function in HIV‐infected pregnant women exposed to HAART therapy
Author(s) -
De la Calle M.,
Rodriguez R.,
Deirós L.,
Bartha J. L.
Publication year - 2015
Publication title -
prenatal diagnosis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.956
H-Index - 97
eISSN - 1097-0223
pISSN - 0197-3851
DOI - 10.1002/pd.4549
Subject(s) - medicine , fetus , obstetrics , gestation , prospective cohort study , cardiac function curve , pregnancy , umbilical artery , human immunodeficiency virus (hiv) , cardiology , immunology , heart failure , biology , genetics
Objective Previous studies have suggested that antiretroviral therapy in human immunodeficiency virus (HIV)‐infected pregnant women can cause alterations in cardiac structure and function in fetuses or children, although the results are not very clear. The aim of this study is to assess whether or not these alterations are present in the heart of fetuses of HIV‐infected pregnant women, undergoing treatment with highly active antiretroviral therapy (HAART). Study Design We performed a prospective study on 29 consecutive HIV‐positive pregnant women treated with HAART and 70 consecutive HIV‐negative pregnant women as controls. Fetal cardiac biometry and function was evaluated by echocardiography at 30–32 weeks of gestation. Fetal biometry, estimated fetal weight and umbilical artery Doppler were also measured. Results We found E/A tricuspid ratio values slightly increased (0.84 vs 0.80, p = 0.03) and diastolic length shortened (49.7 vs 51.7%, p = 0.03) in the HIV‐infected group. The rest of the biometric and functional cardiac parameters were not different between both groups. There were no cases of vertical transmission of HIV infection. Conclusion In HIV‐infected pregnant women treated with HAART, no significant changes are showed in fetal cardiac parameters. © 2015 John Wiley & Sons, Ltd.